Anti-Tumor Drugs Market Report 2025

The anti-tumor drugs market size has grown rapidly in recent years. It will grow from $186.18 billion in 2024 to $206.81 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. Growth during the historic period can be attributed to rising cancer incidence, increased adoption of targeted therapies and immunotherapies, a surge in clinical trials, expanded use of personalized medicine approaches, and higher healthcare spending.

The anti-tumor drugs market size is expected to see rapid growth in the next few years. It will grow to $311.86 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. Growth in the forecast period is expected to be driven by an increasing emphasis on precision medicine, a expanding pipeline of novel anti-tumor agents, rising demand for oral oncology drugs, greater penetration of anti-tumor drugs in emerging markets, and an increase in clinical trials targeting rare and refractory tumors. Key trends during this period include the development of bispecific antibodies for solid tumors, integration of genomic biomarkers in treatment planning, incorporation of companion diagnostics alongside drug launches, innovations in antibody-drug conjugates, and advancements in tumor microenvironment modulators.

The rising incidence of cancer is expected to drive growth in the anti-tumor drugs market moving forward. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and potentially metastasize through the blood and lymphatic systems. The increase in cancer cases is mainly attributed to unhealthy lifestyle factors such as poor diet, physical inactivity, smoking, excessive alcohol use, and prolonged exposure to environmental pollutants, all of which significantly elevate the risk of developing various cancers. Anti-tumor drugs work by targeting and eliminating malignant cells, slowing tumor growth, and preventing disease progression. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that cancer diagnoses in Australia reached 160,570 cases in 2022, up by 3,789 from 156,781 cases in 2021. Consequently, the growing number of cancer cases is boosting the anti-tumor drug market.

Key players in the anti-tumor drugs market are concentrating on developing precision therapies, such as targeted treatments for breast cancer, to improve therapeutic outcomes in hormone receptor-positive metastatic cases. Targeted breast cancer treatments involve precision medicines that specifically interfere with cancer cell growth pathways, reducing harm to healthy cells and enhancing patient tolerance. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, introduced Palbociclib, a new anti-cancer drug in India for advanced breast cancer. Palbociclib is a selective oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial in regulating the cell cycle. By blocking the transition from the G1 phase to the S phase, this drug causes cell cycle arrest, thereby inhibiting tumor growth. It is mainly used for hormone receptor-positive, HER2-negative advanced breast cancer, targeting the uncontrolled proliferation of cancer cells.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition aims to strengthen AbbVie’s oncology portfolio, expand its pipeline of innovative cancer treatments, and reinforce its position in the global biopharmaceutical market. ImmunoGen, Inc., based in the US, is a biotechnology company specializing in anti-tumor drugs.

Major players in the anti-tumor drugs market are Pfizer Inc, Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG., GlaxoSmithKline plc, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Astellas Pharma Inc., Incyte Corporation, BeOne Medicines Inc., Getwell Oncology Pvt Ltd., Shanghai Haihe Pharmaceutical Co. Ltd.

North America was the largest region in the anti-tumor drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-tumor drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-tumor drugs market consists of sales of opdevlimidivo, avastin, herceptin, and revlimid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creatorsA of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-tumor drugs market research report is one of a series of new reports that provides anti-tumor drugs market statistics, including anti-tumor drugs global market size, regional shares, competitors with anti-tumor drugs market share, detailed anti-tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-tumor drugs industry. The anti-tumor drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-tumor drugs are medications aimed at preventing, inhibiting, or treating tumor growth, especially in cancer. They function by destroying cancer cells, halting their division, blocking growth-promoting signals, or activating the immune system to attack cancer cells. These drugs are commonly used alone or alongside surgery, radiation, or other treatments to enhance patient outcomes and lower the chances of cancer recurrence.

The primary categories of anti-tumor drugs include cytotoxic drugs, targeted therapies, hormonal therapies, immunotherapies, and others. Cytotoxic drugs specifically kill or damage cells and are mainly employed to destroy cancer cells by disrupting their growth and division. These medications treat various cancers such as lung, breast, colorectal, prostate, and more. They are administered via multiple routes, including oral and injectable forms, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.